GLP-1 therapies, including injectable and oral semaglutide, are increasingly used to support weight management and reduce cardiometabolic risk. While these therapies can be highly effective, optimal outcomes depend on continuous follow-up, scheduled monitoring, and early identification of any adverse effects, particularly during dose escalation and long-term use.
Cardiac RMS provides a scalable clinical framework to support GLP-1 therapy through Principal Care Management (PCM) and Remote Patient Monitoring (RPM) programs, extending provider oversight beyond the office setting.
Weight trajectory is a key clinical marker in patients treated with GLP-1 medications. Cardiac RMS deploys FDA-compliant, Bluetooth or Cellular connected scales that automatically transmit weight data into the patient record. This gives clinicians a clear view of weight trends, supports early intervention for rapid weight loss or non-response, and minimizes the need for additional in-office visits.
Appetite suppression associated with GLP-1 therapy increases the risk of inadequate caloric intake, protein deficiency, and unintentional lean muscle loss. Cardiac RMS nursing teams provide structured dietary education focused on protein adequacy, hydration, nutrient density, and sustainable eating patterns. Education is reinforced longitudinally and adjusted based on patient tolerance and clinical response.
Loss of skeletal muscle mass is a well-recognized concern during medication-assisted weight loss. Cardiac RMS reinforces appropriate physical activity guidance, including resistance and strength-preserving movement when clinically appropriate. Activity recommendations are individualized to patient ability and clinical conditions.
GLP-1 therapies are commonly associated with gastrointestinal symptoms, fatigue, and intolerance—particularly during titration. Through structured PCM workflows, Cardiac RMS monitors medication adherence, assesses patient-reported side effects, and escalates clinically relevant concerns to the prescribing provider. This proactive surveillance supports continuity of therapy while reducing preventable discontinuation.
After initial onboarding and more frequent support at the outset, Cardiac RMS provides standardized monthly follow-ups, with the ability to increase contact frequency based on clinical need. These touchpoints help keep patients engaged, reinforce education, and provide useful data between visits.
By integrating PCM and RPM services for patients on GLP-1 therapy, Cardiac RMS enables practices to maintain oversight, improve adherence, and enhance patient safety without adding operational strain. The program supports evidence-based management, strengthens documentation, and supports reimbursement for ongoing care management.
The positive outcome: improved continuity of care, earlier intervention, and safer long-term GLP-1 therapy management, delivered through a clinically structured, nurse-led remote care model.
Keeping device patients connected to remote monitoring takes more than technology—it takes the right processes, follow-up, and patient engagement. The Connected Patient: A Field Guide from Cardiac RMS shares practical strategies for enrollment, first transmissions, ongoing connectivity, reconnection, and more. It also gives you a closer look at the real-world workflow, staffing demands, and patient touchpoints that can make the difference between simply enrolling patients and keeping them consistently connected.
Complete the short form below to download your complimentary copy.
